Novartis, Invivoscribe to Develop Companion Test for Acute Myeloid Leukemia Rx Midostaurin

Invivoscribe and Novartis plan to develop an FDA-approved companion test for the investigational AML drug midostaurin and simultaneously launch the drug/test combination worldwide.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.